E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

被引：0
|
作者：
Hochster, Howard S.
Catalano, Paul J.
Mitchell, Edith P.
Cohen, Deirdre Jill
O'Dwyer, Peter J.
Benson, Al Bowen
机构：
[1] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[4] NYU, Inst Canc, New York, NY USA
[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3665
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2013, 24
  • [22] Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
    Ye Chen
    Dan Cao
    Feng Bi
    Qiu Li
    Meng Qiu
    Medical Oncology, 2014, 31
  • [23] Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
    Chen, Ye
    Cao, Dan
    Bi, Feng
    Li, Qiu
    Qiu, Meng
    MEDICAL ONCOLOGY, 2014, 31 (05)
  • [24] A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
    Townsend, A. R.
    Pirc, L.
    Hardingham, J.
    Karapetis, C. S.
    Tebbutt, N. C.
    Singhal, N.
    Price, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
    He Wen-zhuo
    Xia Liang-ping
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (03):
  • [26] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Myoung Joo Kang
    Yong Sang Hong
    Kyu-pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Min-Hee Ryu
    Jae-Lyun Lee
    Heung Moon Chang
    Mi-Jung Kim
    Hee Jin Chang
    Yoon-Koo Kang
    Tae Won Kim
    Investigational New Drugs, 2012, 30 : 1607 - 1613
  • [27] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Kang, Myoung Joo
    Hong, Yong Sang
    Kim, Kyu-pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Chang, Heung Moon
    Kim, Mi-Jung
    Chang, Hee Jin
    Kang, Yoon-Koo
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1607 - 1613
  • [28] Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
    Shiozawa, Manabu
    Sunakawa, Yu
    Watanabe, Takanori
    Ota, Hirofumi
    Yasui, Hisateru
    Yabuno, Taichi
    Tei, Mitsuyoshi
    Kochi, Mitsugu
    Manaka, Dai
    Ohori, Hisatsugu
    Yamaguchi, Tatsuro
    Sagawa, Tamotsu
    Kotaka, Masahito
    Kubota, Yutaro
    Sekikawa, Takashi
    Nakamura, Masato
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    Tsuji, Akihito
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [29] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [30] USE OF CETUXIMAB-BASED THERAPY AS SECOND-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CARCINOMAS (mCRC)
    Gurusamy, P.
    Hashim, M. A.
    Nguyen, H.
    Iddawela, M.
    Wong, Z. W.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 55 - 55
12345